Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor α together with naive dendritic cells elicits significant suppression of tumor growth without toxicity

Alireza Kianmanesh, Neil R. Hackett, Jay M. Lee, Toshiaki Kikuchi, Robert J. Korst, Ronald Crystal

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Although tumor necrosis factor α (TNF-α) is a potent cytokine with a myriad of innate immune antitumor properties, systemic administration of TNF-α is associated with significant toxicity, limiting the use of the TNF-α protein as an antitumor therapeutic. On the basis of the knowledge that dendritic cells (DCs) play a central role in initiating antitumor adaptive immune responses, we hypothesized that intratumoral administration of low doses of an adenovirus encoding TNF-α (AdTNF-α) together with syngeneic DCs would act synergistically to suppress preexisting tumors. As a model, four different tumor cell lines, all resistant in vitro to the TNF-α protein, were implanted in syngeneic mice, and established tumors received intratumor AdTNF-α alone or in combination with DCs. At high doses (109PFU), AdTNF-α alone suppressed tumor growth, but was associated with systemic toxicity. A 100-fold lower AdTNF-α concentration (107PFU) or high doses of the control vector AdNull had no systemic toxicity, but also minimal suppression of tumor growth. In contrast, local administration of the low dose (107PFU) of AdTNF-α in combination with syngeneic DCs (AdTNF-α + DCs) elicited marked tumor suppression without toxicity. Administration of AdTNF-α + DCs into tumors elicited tumor-specific cytotoxic T cells and protected animals against subsequent challenge with the same tumor, suggesting that AdTNF-α + DC therapy induced tumor-specific adaptive immune host responses. Consistent with this concept, studies with syngeneic knockout mice showed that MHC class I molecules on DCs as well as CD8+T cells were necessary for the antitumor effect of intratumor AdTNF-α + DCs. These data demonstrate that the combination of intratumoral administration of the TNF-α cDNA together with naive DCs can evoke tumor suppression without systemic toxicity, providing a new paradigm for the use of TNF-α as antitumor therapy.

Original languageEnglish
Pages (from-to)2035-2049
Number of pages15
JournalHuman Gene Therapy
Volume12
Issue number17
DOIs
Publication statusPublished - 20 Nov 2001
Externally publishedYes

Fingerprint

Adenoviridae
Dendritic Cells
Tumor Necrosis Factor-alpha
Growth
Neoplasms
Adaptive Immunity
T-Lymphocytes
Cell- and Tissue-Based Therapy
Tumor Cell Line
Knockout Mice
Proteins
Complementary DNA
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor α together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. / Kianmanesh, Alireza; Hackett, Neil R.; Lee, Jay M.; Kikuchi, Toshiaki; Korst, Robert J.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 12, No. 17, 20.11.2001, p. 2035-2049.

Research output: Contribution to journalArticle

@article{a27e10ecf51140b4954bd8167441903f,
title = "Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor α together with naive dendritic cells elicits significant suppression of tumor growth without toxicity",
abstract = "Although tumor necrosis factor α (TNF-α) is a potent cytokine with a myriad of innate immune antitumor properties, systemic administration of TNF-α is associated with significant toxicity, limiting the use of the TNF-α protein as an antitumor therapeutic. On the basis of the knowledge that dendritic cells (DCs) play a central role in initiating antitumor adaptive immune responses, we hypothesized that intratumoral administration of low doses of an adenovirus encoding TNF-α (AdTNF-α) together with syngeneic DCs would act synergistically to suppress preexisting tumors. As a model, four different tumor cell lines, all resistant in vitro to the TNF-α protein, were implanted in syngeneic mice, and established tumors received intratumor AdTNF-α alone or in combination with DCs. At high doses (109PFU), AdTNF-α alone suppressed tumor growth, but was associated with systemic toxicity. A 100-fold lower AdTNF-α concentration (107PFU) or high doses of the control vector AdNull had no systemic toxicity, but also minimal suppression of tumor growth. In contrast, local administration of the low dose (107PFU) of AdTNF-α in combination with syngeneic DCs (AdTNF-α + DCs) elicited marked tumor suppression without toxicity. Administration of AdTNF-α + DCs into tumors elicited tumor-specific cytotoxic T cells and protected animals against subsequent challenge with the same tumor, suggesting that AdTNF-α + DC therapy induced tumor-specific adaptive immune host responses. Consistent with this concept, studies with syngeneic knockout mice showed that MHC class I molecules on DCs as well as CD8+T cells were necessary for the antitumor effect of intratumor AdTNF-α + DCs. These data demonstrate that the combination of intratumoral administration of the TNF-α cDNA together with naive DCs can evoke tumor suppression without systemic toxicity, providing a new paradigm for the use of TNF-α as antitumor therapy.",
author = "Alireza Kianmanesh and Hackett, {Neil R.} and Lee, {Jay M.} and Toshiaki Kikuchi and Korst, {Robert J.} and Ronald Crystal",
year = "2001",
month = "11",
day = "20",
doi = "10.1089/10430340152677395",
language = "English",
volume = "12",
pages = "2035--2049",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "17",

}

TY - JOUR

T1 - Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor α together with naive dendritic cells elicits significant suppression of tumor growth without toxicity

AU - Kianmanesh, Alireza

AU - Hackett, Neil R.

AU - Lee, Jay M.

AU - Kikuchi, Toshiaki

AU - Korst, Robert J.

AU - Crystal, Ronald

PY - 2001/11/20

Y1 - 2001/11/20

N2 - Although tumor necrosis factor α (TNF-α) is a potent cytokine with a myriad of innate immune antitumor properties, systemic administration of TNF-α is associated with significant toxicity, limiting the use of the TNF-α protein as an antitumor therapeutic. On the basis of the knowledge that dendritic cells (DCs) play a central role in initiating antitumor adaptive immune responses, we hypothesized that intratumoral administration of low doses of an adenovirus encoding TNF-α (AdTNF-α) together with syngeneic DCs would act synergistically to suppress preexisting tumors. As a model, four different tumor cell lines, all resistant in vitro to the TNF-α protein, were implanted in syngeneic mice, and established tumors received intratumor AdTNF-α alone or in combination with DCs. At high doses (109PFU), AdTNF-α alone suppressed tumor growth, but was associated with systemic toxicity. A 100-fold lower AdTNF-α concentration (107PFU) or high doses of the control vector AdNull had no systemic toxicity, but also minimal suppression of tumor growth. In contrast, local administration of the low dose (107PFU) of AdTNF-α in combination with syngeneic DCs (AdTNF-α + DCs) elicited marked tumor suppression without toxicity. Administration of AdTNF-α + DCs into tumors elicited tumor-specific cytotoxic T cells and protected animals against subsequent challenge with the same tumor, suggesting that AdTNF-α + DC therapy induced tumor-specific adaptive immune host responses. Consistent with this concept, studies with syngeneic knockout mice showed that MHC class I molecules on DCs as well as CD8+T cells were necessary for the antitumor effect of intratumor AdTNF-α + DCs. These data demonstrate that the combination of intratumoral administration of the TNF-α cDNA together with naive DCs can evoke tumor suppression without systemic toxicity, providing a new paradigm for the use of TNF-α as antitumor therapy.

AB - Although tumor necrosis factor α (TNF-α) is a potent cytokine with a myriad of innate immune antitumor properties, systemic administration of TNF-α is associated with significant toxicity, limiting the use of the TNF-α protein as an antitumor therapeutic. On the basis of the knowledge that dendritic cells (DCs) play a central role in initiating antitumor adaptive immune responses, we hypothesized that intratumoral administration of low doses of an adenovirus encoding TNF-α (AdTNF-α) together with syngeneic DCs would act synergistically to suppress preexisting tumors. As a model, four different tumor cell lines, all resistant in vitro to the TNF-α protein, were implanted in syngeneic mice, and established tumors received intratumor AdTNF-α alone or in combination with DCs. At high doses (109PFU), AdTNF-α alone suppressed tumor growth, but was associated with systemic toxicity. A 100-fold lower AdTNF-α concentration (107PFU) or high doses of the control vector AdNull had no systemic toxicity, but also minimal suppression of tumor growth. In contrast, local administration of the low dose (107PFU) of AdTNF-α in combination with syngeneic DCs (AdTNF-α + DCs) elicited marked tumor suppression without toxicity. Administration of AdTNF-α + DCs into tumors elicited tumor-specific cytotoxic T cells and protected animals against subsequent challenge with the same tumor, suggesting that AdTNF-α + DC therapy induced tumor-specific adaptive immune host responses. Consistent with this concept, studies with syngeneic knockout mice showed that MHC class I molecules on DCs as well as CD8+T cells were necessary for the antitumor effect of intratumor AdTNF-α + DCs. These data demonstrate that the combination of intratumoral administration of the TNF-α cDNA together with naive DCs can evoke tumor suppression without systemic toxicity, providing a new paradigm for the use of TNF-α as antitumor therapy.

UR - http://www.scopus.com/inward/record.url?scp=0035684074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035684074&partnerID=8YFLogxK

U2 - 10.1089/10430340152677395

DO - 10.1089/10430340152677395

M3 - Article

VL - 12

SP - 2035

EP - 2049

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 17

ER -